Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Two Formulations of Sarpogrelate HCl 300mg
NCT03947489Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Mar 2019
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sarpogrelate in Peripheral Arterial Disease (PAD) and arterial occlusion (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration and Area under the plasma concentration versus time curve. Started Mar 2019; status: completed.
02
Drugs
sarpogrelate
03
Conditions
Peripheral Arterial Disease (PAD)arterial occlusion
Beyond the preview
Go deeper on NCT03947489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03947489.